Pasi A. Jänne

Clinical Cancer Research Deputy Editor

Pasi A. Jänne is a recently appointed Deputy Editor of Clinical Cancer Research. He is a Professor of Medicine at Harvard Medical School, the Director of the Lowe Center for Thoracic Oncology, and the Director of the Belfer Center for Applied Cancer Science at the Dana-Farber Cancer Institute. He is a translational medical oncologist focused primarily on studying genetic subsets of lung cancer and identifying novel therapies for lung cancer patients.

An active member of the American Association for Cancer Research since 1999, Dr. Jänne has led numerous committees and presented work at the AACR annual meeting. Most recently, he served as a member of the publications committee and co-chaired the programming committee for the annual meeting from 2016–2018. He has also been an editorial board member of CCR since 2009.

Dr. Jänne has received numerous prestigious awards throughout his career, including honors from the AACR. In 2010, the AACR awarded him the Team Science Award and the Richard and Hinda Rosenthal Memorial Award. Just last year, he received the Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research.

In addition to his work with AACR and positions at Harvard, Dr. Jänne has served on numerous advisory boards in the private sector and occupied leadership positions in major oncology organizations including the American Society of Oncology and the International Association for the Study of Lung Cancer. He has a bachelor’s degree in chemistry from Vassar College, a medical degree and a PhD in Genetics from the University of Pennsylvania, and a Masters in Clinical Investigation from Harvard University.

Dr. Jänne’s recently published articles in AACR journals are listed below.

• Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer
  Bahcall M…Jänne PA. Clinical Cancer Research August 2018.
• A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing
  Lizotte PH…Jänne PA. Cancer Immunology Research September 2018.
• STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
  Skoulidis F…Heymach JV. Cancer Discovery July 2018.
• False-Positive Plasma Genotyping Due to Clonal Hematopoiesis
  Hu Y…Oxnard GR. Clinical Cancer Research September 2018.
• Small-Cell Neuroendocrine Tumors: Cell State Trumps the Oncogenic Driver
  Oser MG and Jänne PA. Clinical Cancer Research April 2018.
• Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study
  Hanna GJ…Lorch JH. Clinical Cancer Research April 2018.